查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1709454

傳染性腸炎治療市場，按治療類型、按病原體類型、按給藥途徑、按配銷通路、按最終用戶、按國家和地區 - 2025 年至 2032 年全球行業分析、市場規模、市場佔有率和預測

Infectious Enteritis Treatment Market, By Treatment Type, By Pathogen Type, By Route of Administration, By Distribution Channel, By End User, By Country, and By Region - Global Industry Analysis, Market Size, Market Share & Forecast from 2025-2032
出版日期: | 出版商: AnalystView Market Insights | 英文 311 Pages | 商品交期: 2-3個工作天內

價格
簡介目錄

報告重點

2024 年傳染性腸炎治療市場規模價值 4.9054 億美元，2025 年至 2032 年的複合年成長率為 7.20%。

傳染性腸炎治療市場-市場動態

食源性疾病盛行率不斷上升，導致全球治療需求增加。

食源性疾病盛行率的上升是傳染性腸炎治療市場的重要動力。受污染的食物和水是細菌、病毒和寄生蟲感染的主要來源，導致腹瀉和胃腸炎等疾病。根據世界衛生組織 (WHO) 統計，食源性疾病每年影響數百萬人，增加了對抗生素、口服補液鹽 (ORS) 和益生菌等有效治療方法的需求。快速的城市化、惡劣的衛生條件以及不安全的食品處理方式導致食源性疾病激增，尤其是在發展中地區。此外，全球旅行和貿易增加了食源性病原體的跨境傳播。抗生素抗藥性菌株的增加進一步推動了先進療法和聯合治療的研究。提高人們意識和衛生習慣的公共衛生運動提高了早期診斷率，促進了市場成長。政府和衛生組織增加對輪狀病毒免疫等疫苗接種計畫的資助也減少了嚴重的病毒性腸炎病例。總體而言，食源性疾病發生率的不斷上升以及相關的健康風險正在推動傳染性腸炎治療市場的擴張。

傳染性腸炎治療市場—關鍵見解

根據我們的研究分析師的分析，預測期內（2025-2032 年）全球市場預計年複合成長率約為 7.20%

根據治療類型細分，預計藥物將在 2024 年佔據最大市場佔有率

根據病原體類型細分，細菌是 2024 年的主要病原體類型

根據給藥途徑細分，口服是 2024 年最主要的給藥途徑

根據配銷通路細分，醫院藥房是 2024 年領先的配銷通路

根據最終用戶細分，醫院是 2024 年領先的最終用戶

按地區分類，北美是 2024 年的主要收入來源

傳染性腸炎治療市場-細分分析：

全球傳染性腸炎治療市場根據治療類型、病原體類型、給藥途徑、配銷通路、最終用戶和地區進行細分。

根據治療類型，市場分為四大類：藥物、療法、疫苗、支持性護理。藥物是傳染性腸炎治療市場中最主要的部分，因為它們在控制細菌、病毒和寄生蟲感染方面發揮著至關重要的作用。抗生素廣泛用於治療細菌性腸炎，而抗病毒藥物和抗寄生蟲藥物分別用於治療病毒和寄生蟲感染。抗生素抗藥性細菌的日益普及進一步推動了對聯合療法和新一代抗生素的需求。口服補液鹽（ORS）對於治療脫水（腸炎的常見併發症）至關重要。無論急性或慢性，藥物的可及性和有效性使其成為主要的治療選擇。此外，網路藥局和遠距醫療服務的興起也改善了患者獲得基本藥物的機會。

依病原體類型，市場分為三類：細菌、病毒、寄生蟲。細菌類藥物在傳染性腸炎治療市場中佔據主導地位，這主要是由於沙門氏菌、大腸桿菌和志賀氏菌等病原體引起的食源性疾病的流行率較高。細菌性腸炎是全球住院的主要原因，增加了對抗生素和支持療法的需求。抗生素抗藥性菌株的出現進一步加速了先進治療方法和聯合藥物療法的研究。受污染的食物和水仍然是主要的傳播來源，尤其是在發展中地區。此外，與不安全食品操作有關的疫情持續促使人們提高意識並採取預防措施。診斷技術的快速進步進一步鞏固了細菌治療領域的主導地位，從而能夠更快地進行治療干預。

傳染性腸炎治療市場-地理洞察

受高昂的醫療支出和先進的醫療基礎設施的推動，北美在傳染性腸炎治療市場佔有相當大的佔有率。由於食源性疾病發生率不斷上升，美國在該地區居於首位，美國疾病管制與預防中心 (CDC) 報告稱，每年約有 4,800 萬例食源性疾病病例。衛生意識的增強以及強力的疫苗接種計劃（如嬰兒輪狀病毒免疫）促進了市場的成長。由於食物和水源受到污染，加拿大的腸炎病例也在增加，對快速診斷工具和有效治療的需求也增加。研究和開發活動十分活躍，重點關注新型抗生素和益生菌，以解決抗生素抗藥性病原體問題。此外，優惠的報銷政策和政府支持公眾健康意識的舉措正在推動市場擴張。遠距醫療和網路藥局的日益成長的趨勢正在提高整個地區治療的可及性。總體而言，北美強大的醫療保健體系、技術進步和預防保健措施正在推動傳染性腸炎治療市場的成長。

美國在北美傳染性腸炎治療市場佔據主導地位，這得益於其食源性疾病的高發性和強大的醫療保健基礎設施。根據美國疾病管制與預防中心 (CDC) 的數據，每年約有 4,800 萬人患有食源性疾病，這導致對抗生素、口服補液鹽 (ORS) 和益生菌等治療方法的需求強勁。該國擁有完善的疫苗接種計劃，包括嬰兒輪狀病毒免疫接種，有助於減少嚴重的病毒性腸炎病例。快速 PCR 檢測等先進的診斷技術正在支援早期發現和有效治療。此外，抗生素抗藥性細菌感染問題日益嚴重，推動了新療法和合併藥物的研究。政府加強措施和公共衛生運動力度，提倡衛生和安全的食品習慣，進一步支持了市場的成長。遠距醫療和網路藥局服務的擴展也提高了全國各地治療的可近性。總體而言，美國市場受到強力的醫療政策、技術進步以及對傳染病的認知不斷提高的推動。

傳染性腸炎治療市場-競爭格局：

傳染性腸炎治療市場競爭激烈，全球多家製藥公司專注於藥物開發、疫苗和支持療法。葛蘭素史克、賽諾菲和默克等主要公司在疫苗生產方面表現突出，尤其是輪狀病毒疫苗，對於預防病毒性腸炎至關重要。輝瑞、強生和拜耳等公司在抗生素領域佔據主導地位，主要治療沙門氏菌和大腸桿菌等細菌感染。諾華和艾伯維等公司推動了益生菌療法的研究，重點是恢復感染後的腸道健康。抗生素抗藥性是細菌性腸炎治療中日益受到關注的問題，市場在開發抗抗生素組合藥物方面競爭激烈。合作、合併和收購是公司擴大投資組合和增強分銷網路的常見策略。此外，對快速診斷工具的投資正在增加，羅氏和吉利德科學等公司整合了先進技術以實現早期檢測。新興企業正專注於具有成本效益的治療方法，以滿足發展中地區的需求。總體而言，強大的研發管道、技術進步和策略合作正在塑造傳染性腸炎治療市場的競爭態勢。

最新動態：

2022 年 11 月，葛蘭素史克公司獲得 FDA 批准，可以採用新的口服給藥施藥器方式注射其輪狀病毒疫苗 ROTARIX。這項進步簡化了醫療保健提供者的準備工作，無需重新配製劑量，提供了更便捷的選擇，並增強了葛蘭素史克的業務組合。

目錄

第1章：傳染性腸炎治療市場概述

  • 研究範圍
  • 市場估計年限

第2章：執行摘要

  • 市場片段
    • 傳染性腸炎治療市場（依治療類型分類）
    • 傳染性腸炎治療市場（按病原體類型）
    • 傳染性腸炎治療市場依給藥途徑分類
    • 傳染性腸炎治療市場（依配銷通路）
    • 傳染性腸炎治療市場（按最終用戶）摘要
    • 傳染性腸炎治療市場（按國家/地區）
    • 傳染性腸炎治療市場（按地區）
  • 競爭洞察

第3章：傳染性腸炎治療主要市場趨勢

  • 傳染性腸炎治療市場促進因素
    • 市場促進因素的影響分析
  • 傳染性腸炎治療市場限制
    • 市場限制的影響分析
  • 傳染性腸炎治療市場機遇
  • 傳染性腸炎治療市場未來趨勢

第4章：傳染性腸炎治療產業研究

  • PEST分析
  • 波特五力分析
  • 成長前景圖
  • 規範架構分析

第5章：傳染性腸炎治療市場：地緣政治緊張局勢升級的影響

  • COVID-19 疫情的影響
  • 俄烏戰爭的影響
  • 中東衝突的影響

第6章：傳染性腸炎治療市場格局

  • 傳染性腸炎治療市佔率分析（2024年）
  • 按主要製造商分類的細分數據
    • 成熟玩家分析
    • 新興企業分析

第7章：傳染性腸炎治療市場－依治療類型

  • 概述
    • 按治療類型分類的細分市場佔有率分析
    • 藥物
    • 療法
    • 疫苗
    • 支持治療

第8章：傳染性腸炎治療市場－依病原體類型

  • 概述
    • 按病原體類型進行細分佔有率分析
    • 細菌
    • 病毒性的
    • 寄生

第9章：傳染性腸炎治療市場－依給藥途徑

  • 概述
    • 按給藥途徑分類的細分市佔率分析
    • 口服
    • 靜脈注射（IV）
    • 注射劑

第 10 章：傳染性腸炎治療市場 - 按配銷通路

  • 概述
    • 按病原體類型進行細分佔有率分析
    • 醫院藥房
    • 零售藥局
    • 網路藥局

第 11 章：傳染性腸炎治療市場 - 按最終用戶

  • 概述
    • 按最終用戶細分的佔有率分析
    • 醫院
    • 診所
    • 門診手術中心（ASC）
    • 零售藥局
    • 網路藥局

第 12 章：傳染性腸炎治療市場 - 按地區

  • 介紹
    • 按地區分類的細分市場佔有率分析
  • 北美洲
    • 概述
    • 北美傳染性腸炎治療主要製造商
    • 北美市場規模及預測（按國家/地區）
    • 北美市場規模和預測，按治療類型
    • 北美市場規模及預測（按病原體類型）
    • 北美市場規模及預測（按給藥途徑）
    • 北美市場規模及預測（按配銷通路）
    • 北美市場規模和預測（按最終用戶）
    • 美國
    • 加拿大
  • 歐洲
    • 概述
    • 歐洲傳染性腸炎治療主要製造商
    • 歐洲市場規模及預測（按國家/地區）
    • 歐洲市場規模及預測（按治療類型）
    • 歐洲市場規模及預測（按病原體類型）
    • 歐洲市場規模及預測（依管理途徑）
    • 歐洲市場規模及預測（按配銷通路）
    • 歐洲市場規模和預測（按最終用戶）
    • 德國
    • 英國
    • 法國
    • 義大利
    • 西班牙
    • 荷蘭
    • 瑞典
    • 俄羅斯
    • 波蘭
    • 歐洲其他地區
  • 亞太地區 (APAC)
    • 概述
    • 亞太地區傳染性腸炎治療主要製造商
    • 亞太地區市場規模及預測（依國家）
    • 亞太地區市場規模及預測（依治療類型）
    • 亞太地區市場規模及預測（依病原體類型）
    • 亞太地區市場規模及預測（依管理途徑）
    • 亞太地區市場規模及預測（按配銷通路）
    • 亞太地區市場規模及預測（依最終用戶）
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲
    • 印尼
    • 泰國
    • 菲律賓
    • 亞太地區其他地區
  • 拉丁美洲（LATAM）
    • 概述
    • 拉丁美洲傳染性腸炎治療主要製造商
    • 拉丁美洲市場規模及預測（按國家/地區）
    • 拉丁美洲市場規模及預測（按治療類型）
    • 拉丁美洲市場規模及預測（按病原體類型）
    • 拉丁美洲市場規模及預測（依管理途徑）
    • 拉丁美洲市場規模及預測（按配銷通路）
    • LATAM 規模和預測（按最終用戶）
    • 巴西
    • 墨西哥
    • 阿根廷
    • 哥倫比亞
    • 拉丁美洲其他地區
  • 中東和非洲
    • 概述
    • 中東和非洲傳染性腸炎治療主要製造商
    • 中東和非洲市場規模及預測（按國家/地區）
    • 中東和非洲市場規模及預測（按治療類型）
    • 中東和非洲市場規模及預測（按病原體類型）
    • 中東和非洲市場規模及預測（按管理途徑）
    • 中東和非洲市場規模及預測（按配銷通路）
    • 中東和非洲市場規模及預測（按最終用戶）
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 以色列
    • 土耳其
    • 阿爾及利亞
    • 埃及
    • MEA 其餘地區

第 13 章：傳染性腸炎治療產業主要供應商分析

  • 競爭儀錶板
    • Competitive Benchmarking
    • Competitive Positioning
  • 公司簡介
    • GlaxoSmithKline plc
    • Sanofi SA
    • Johnson & Johnson
    • Merck & Co., Inc.
    • Pfizer Inc.
    • Bayer AG
    • Novartis AG
    • AbbVie Inc.
    • Eli Lilly and Company
    • F. Hoffmann-La Roche Ltd
    • Takeda Pharmaceutical Company Limited
    • AstraZeneca plc
    • Bristol-Myers Squibb Company
    • Boehringer Ingelheim International GmbH
    • Cipla Limited
    • Gilead Sciences, Inc.
    • Sun Pharmaceutical Industries Ltd

第 14 章：360 度分析師視角

第 15 章：附錄

  • 研究方法
  • 參考
  • 縮寫
  • 免責聲明
  • 聯絡我們
簡介目錄
Product Code: ANV4902

REPORT HIGHLIGHT

Infectious Enteritis Treatment Market size was valued at US$ 490.54 Million in 2024, expanding at a CAGR of 7.20% from 2025 to 2032.

The Infectious Enteritis Treatment Market focuses on medications, therapies, and interventions for managing infectious enteritis, an inflammation of the intestines caused by pathogens such as bacteria, viruses, or parasites. This condition leads to symptoms like diarrhea, abdominal pain, nausea, and vomiting. Common causes include rotavirus, norovirus, E. coli, and Salmonella. Treatment options vary based on the infection type and severity, including oral rehydration therapy (ORT), antibiotics, antivirals, and probiotics to restore gut health. Hospitals, clinics, and pharmacies are key providers of these treatments. Increased prevalence of foodborne illnesses and water contamination has fueled market demand. Advancements in rapid diagnostic tools support early detection and timely treatment. Government initiatives promoting awareness and vaccination programs, such as rotavirus immunization, are contributing to market growth. Regions with limited sanitation infrastructure experience a higher burden, driving demand for affordable and accessible treatments. Pharmaceutical companies are actively investing in research to develop targeted therapies and combination drugs to combat resistant pathogens. Overall, the market continues to expand, driven by growing healthcare needs and technological advancements in diagnostics and therapeutics.

Infectious Enteritis Treatment Market- Market Dynamics

Rising prevalence of foodborne illnesses increasing treatment demand globally.

Rising prevalence of foodborne illnesses is a significant driver for the infectious enteritis treatment market. Contaminated food and water are major sources of bacterial, viral, and parasitic infections, leading to conditions such as diarrhea and gastroenteritis. According to the World Health Organization (WHO), foodborne diseases affect millions of people annually, increasing the demand for effective treatments like antibiotics, oral rehydration solutions (ORS), and probiotics. Rapid urbanization, poor sanitation, and unsafe food handling practices contribute to the surge in foodborne illnesses, especially in developing regions. Additionally, global travel and trade have increased the spread of foodborne pathogens across borders. The rise in antibiotic-resistant strains of bacteria has further driven research into advanced therapies and combination treatments. Public health campaigns promoting awareness and hygiene have improved early diagnosis rates, boosting market growth. Increased funding from governments and health organizations for vaccination programs, such as rotavirus immunization, is also reducing severe cases of viral enteritis. Overall, the growing incidence of foodborne illnesses and the associated health risks are driving the expansion of the infectious enteritis treatment market.

Infectious Enteritis Treatment Market- Key Insights

As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 7.20% over the forecast period (2025-2032)

Based on Treatment Type segmentation, Medications was predicted to show maximum market share in the year 2024

Based on Pathogen Type segmentation, bacterial was the leading Pathogen Type in 2024

Based on Route of Administration segmentation, Oral was the leading Route of Administration in 2024

Based on Distribution Channel segmentation, Hospital Pharmacies was the leading Distribution Channel in 2024

Based on end-user segmentation, Hospitals was the leading end user in 2024

On the basis of region, North America was the leading revenue generator in 2024

Infectious Enteritis Treatment Market- Segmentation Analysis:

The Global Infectious Enteritis Treatment Market is segmented on the basis of Treatment Type, Pathogen Type, Route of Administration, Distribution Channel, End User, and Region.

The market is divided into four categories based on Treatment Type: Medications, Therapies, Vaccines, Supportive Care. Medications are the most dominant segment in the infectious enteritis treatment market, driven by their crucial role in managing bacterial, viral, and parasitic infections. Antibiotics are widely prescribed for bacterial enteritis, while antivirals and antiparasitic drugs address viral and parasitic infections, respectively. The growing prevalence of antibiotic-resistant bacteria has further boosted demand for combination therapies and new-generation antibiotics. Oral rehydration solutions (ORS) are essential for managing dehydration, a common complication of enteritis. The accessibility and effectiveness of medications in both acute and chronic cases make them a primary treatment option. Additionally, the rise of online pharmacies and telemedicine services has improved patient access to essential medications.

The market is divided into three categories based on Pathogen Type: Bacterial, Viral, Parasitic. The bacterial segment is the most dominant in the infectious enteritis treatment market, driven by the high prevalence of foodborne illnesses caused by pathogens such as Salmonella, E. coli, and Shigella. Bacterial enteritis is a leading cause of hospitalizations globally, increasing demand for antibiotics and supportive therapies. The rise of antibiotic-resistant strains has further accelerated research into advanced treatments and combination drug therapies. Contaminated food and water remain major transmission sources, especially in developing regions. Additionally, outbreaks linked to unsafe food practices continue to drive awareness and preventive measures. The bacterial segment's dominance is further supported by rapid diagnostic advancements, enabling quicker treatment interventions.

Infectious Enteritis Treatment Market- Geographical Insights

North America holds a significant share of the infectious enteritis treatment market, driven by high healthcare expenditure and advanced medical infrastructure. The United States leads the region due to a rising prevalence of foodborne illnesses, with the Centers for Disease Control and Prevention (CDC) reporting approximately 48 million foodborne illness cases annually. Increased awareness of hygiene and sanitation, along with strong vaccination programs, such as rotavirus immunization for infants, contribute to market growth. Canada is also witnessing a rise in enteritis cases, driven by contaminated food and water sources, increasing demand for rapid diagnostic tools and effective treatments. Research and development activities are robust, focusing on new antibiotics and probiotics to address antibiotic-resistant pathogens. Additionally, favorable reimbursement policies and government initiatives supporting public health awareness are boosting market expansion. The growing trend of telemedicine and online pharmacies is improving accessibility to treatments across the region. Overall, North America's strong healthcare system, technological advancements, and preventive care initiatives are driving growth in the infectious enteritis treatment market.

The United States dominates the infectious enteritis treatment market in North America, driven by a high prevalence of foodborne illnesses and robust healthcare infrastructure. According to the Centers for Disease Control and Prevention (CDC), approximately 48 million people suffer from foodborne illnesses annually, contributing to a strong demand for treatments such as antibiotics, oral rehydration solutions (ORS), and probiotics. The country has well-established vaccination programs, including rotavirus immunization for infants, which helps reduce severe cases of viral enteritis. Advanced diagnostic technologies, such as rapid PCR testing, are supporting early detection and effective treatment. Additionally, the growing issue of antibiotic-resistant bacterial infections is driving research into new therapies and combination drugs. Increased government initiatives and public health campaigns to promote hygiene and safe food practices are further supporting market growth. The expansion of telemedicine and online pharmacy services has also improved accessibility to treatments across the country. Overall, the U.S. market is propelled by strong healthcare policies, technological advancements, and increasing awareness about infectious diseases.

Infectious Enteritis Treatment Market- Competitive Landscape:

The infectious enteritis treatment market is highly competitive, with several global pharmaceutical companies focusing on drug development, vaccines, and supportive therapies. Key players like GlaxoSmithKline, Sanofi, and Merck are prominent in vaccine production, particularly for rotavirus, which is crucial in preventing viral enteritis. Companies such as Pfizer, Johnson & Johnson, and Bayer dominate the antibiotic segment, addressing bacterial infections like Salmonella and E. coli. Increasing research into probiotic therapies is driven by companies like Novartis and AbbVie, focusing on restoring gut health post-infection. The market is witnessing intense competition in developing combination drugs to combat antibiotic resistance, a growing concern in bacterial enteritis treatment. Partnerships, mergers, and acquisitions are common strategies as companies aim to expand their portfolios and enhance distribution networks. Additionally, investments in rapid diagnostic tools are increasing, with firms like Roche and Gilead Sciences integrating advanced technologies for early detection. Emerging players are focusing on cost-effective therapies to meet demand in developing regions. Overall, strong R&D pipelines, technological advancements, and strategic collaborations are shaping the competitive dynamics of the infectious enteritis treatment market.

Recent Developments:

In November 2022, GSK plc received FDA approval for a new oral-dosing applicator-only presentation of ROTARIX, its rotavirus vaccine. This advancement simplifies preparation for healthcare providers by removing the need for dose reconstitution, offering a more convenient option and enhancing GSK's business portfolio.

SCOPE OF THE REPORT

The scope of this report covers the market by its major segments, which include as follows:

GLOBAL INFECTIOUS ENTERITIS TREATMENT MARKET KEY PLAYERS- DETAILED COMPETITIVE INSIGHTS

  • GlaxoSmithKline plc
  • Sanofi S.A.
  • Johnson & Johnson
  • Merck & Co., Inc.
  • Pfizer Inc.
  • Bayer AG
  • Novartis AG
  • AbbVie Inc.
  • Eli Lilly and Company
  • F. Hoffmann-La Roche Ltd
  • Takeda Pharmaceutical Company Limited
  • AstraZeneca plc
  • Bristol-Myers Squibb Company
  • Boehringer Ingelheim International GmbH
  • Cipla Limited
  • Gilead Sciences, Inc.
  • Sun Pharmaceutical Industries Ltd

GLOBAL INFECTIOUS ENTERITIS TREATMENT MARKET, BY TREATMENT TYPE- MARKET ANALYSIS, 2019 - 2032

  • Medications
  • Therapies
  • Vaccines
  • Supportive Care

GLOBAL INFECTIOUS ENTERITIS TREATMENT MARKET, BY PATHOGEN TYPE- MARKET ANALYSIS, 2019 - 2032

  • Bacterial
  • Viral
  • Parasitic

GLOBAL INFECTIOUS ENTERITIS TREATMENT MARKET, BY ROUTE OF ADMINISTRATION- MARKET ANALYSIS, 2019 - 2032

  • Oral
  • Intravenous (IV)
  • Injectable

GLOBAL INFECTIOUS ENTERITIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL- MARKET ANALYSIS, 2019 - 2032

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

GLOBAL INFECTIOUS ENTERITIS TREATMENT MARKET, BY END USER- MARKET ANALYSIS, 2019 - 2032

  • Hospitals
  • Clinics
  • Ambulatory Surgical Centers (ASCs)
  • Retail Pharmacies
  • Online Pharmacies

GLOBAL INFECTIOUS ENTERITIS TREATMENT MARKET, BY REGION- MARKET ANALYSIS, 2019 - 2032

  • North America
  • U.S.
  • Canada
  • Europe
  • Germany
  • UK
  • France
  • Italy
  • Spain
  • The Netherlands
  • Sweden
  • Russia
  • Poland
  • Rest of Europe
  • Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Australia
  • Indonesia
  • Thailand
  • Philippines
  • Rest of APAC
  • Latin America
  • Brazil
  • Mexico
  • Argentina
  • Colombia
  • Rest of LATAM
  • The Middle East and Africa
  • Saudi Arabia
  • UAE
  • Israel
  • Turkey
  • Algeria
  • Egypt
  • Rest of MEA

Table of Contents

1. Infectious Enteritis Treatment Market Overview

  • 1.1. Study Scope
  • 1.2. Market Estimation Years

2. Executive Summary

  • 2.1. Market Snippet
    • 2.1.1. Infectious Enteritis Treatment Market Snippet by Treatment Type
    • 2.1.2. Infectious Enteritis Treatment Market Snippet by Pathogen Type
    • 2.1.3. Infectious Enteritis Treatment Market Snippet by Route of Administration
    • 2.1.4. Infectious Enteritis Treatment Market Snippet by Distribution Channel
    • 2.1.5. Infectious Enteritis Treatment Market Snippet by End User
    • 2.1.6. Infectious Enteritis Treatment Market Snippet by Country
    • 2.1.7. Infectious Enteritis Treatment Market Snippet by Region
  • 2.2. Competitive Insights

3. Infectious Enteritis Treatment Key Market Trends

  • 3.1. Infectious Enteritis Treatment Market Drivers
    • 3.1.1. Impact Analysis of Market Drivers
  • 3.2. Infectious Enteritis Treatment Market Restraints
    • 3.2.1. Impact Analysis of Market Restraints
  • 3.3. Infectious Enteritis Treatment Market Opportunities
  • 3.4. Infectious Enteritis Treatment Market Future Trends

4. Infectious Enteritis Treatment Industry Study

  • 4.1. PEST Analysis
  • 4.2. Porter's Five Forces Analysis
  • 4.3. Growth Prospect Mapping
  • 4.4. Regulatory Framework Analysis

5. Infectious Enteritis Treatment Market: Impact of Escalating Geopolitical Tensions

  • 5.1. Impact of COVID-19 Pandemic
  • 5.2. Impact of Russia-Ukraine War
  • 5.3. Impact of Middle East Conflicts

6. Infectious Enteritis Treatment Market Landscape

  • 6.1. Infectious Enteritis Treatment Market Share Analysis, 2024
  • 6.2. Breakdown Data, by Key Manufacturer
    • 6.2.1. Established Players' Analysis
    • 6.2.2. Emerging Players' Analysis

7. Infectious Enteritis Treatment Market - By Treatment Type

  • 7.1. Overview
    • 7.1.1. Segment Share Analysis, By Treatment Type, 2024 & 2032 (%)
    • 7.1.2. Medications
    • 7.1.3. Therapies
    • 7.1.4. Vaccines
    • 7.1.5. Supportive Care

8. Infectious Enteritis Treatment Market - By Pathogen Type

  • 8.1. Overview
    • 8.1.1. Segment Share Analysis, By Pathogen Type, 2024 & 2032 (%)
    • 8.1.2. Bacterial
    • 8.1.3. Viral
    • 8.1.4. Parasitic

9. Infectious Enteritis Treatment Market - By Route of Administration

  • 9.1. Overview
    • 9.1.1. Segment Share Analysis, By Route of Administration, 2024 & 2032 (%)
    • 9.1.2. Oral
    • 9.1.3. Intravenous (IV)
    • 9.1.4. Injectable

10. Infectious Enteritis Treatment Market - By Distribution Channel

  • 10.1. Overview
    • 10.1.1. Segment Share Analysis, By Pathogen Type, 2024 & 2032 (%)
    • 10.1.2. Hospital Pharmacies
    • 10.1.3. Retail Pharmacies
    • 10.1.4. Online Pharmacies

11. Infectious Enteritis Treatment Market - By End User

  • 11.1. Overview
    • 11.1.1. Segment Share Analysis, By End User, 2024 & 2032 (%)
    • 11.1.2. Hospitals
    • 11.1.3. Clinics
    • 11.1.4. Ambulatory Surgical Centers (ASCs)
    • 11.1.5. Retail Pharmacies
    • 11.1.6. Online Pharmacies

12. Infectious Enteritis Treatment Market- By Geography

  • 12.1. Introduction
    • 12.1.1. Segment Share Analysis, By Geography, 2024 & 2032 (%)
  • 12.2. North America
    • 12.2.1. Overview
    • 12.2.2. Infectious Enteritis Treatment Key Manufacturers in North America
    • 12.2.3. North America Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.2.4. North America Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
    • 12.2.5. North America Market Size and Forecast, By Pathogen Type, 2019 - 2032 (US$ Million)
    • 12.2.6. North America Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 12.2.7. North America Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.2.8. North America Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.2.9. U.S.
      • 12.2.9.1. Overview
      • 12.2.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.2.9.3. U.S. Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 12.2.9.4. U.S. Market Size and Forecast, By Pathogen Type, 2019 - 2032 (US$ Million)
      • 12.2.9.5. U.S. Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.2.9.6. U.S. Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 12.2.9.7. U.S. Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.2.10. Canada
      • 12.2.10.1. Overview
      • 12.2.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.2.10.3. Canada Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 12.2.10.4. Canada Market Size and Forecast, By Pathogen Type, 2019 - 2032 (US$ Million)
      • 12.2.10.5. Canada Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.2.10.6. Canada Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 12.2.10.7. Canada Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 12.3. Europe
    • 12.3.1. Overview
    • 12.3.2. Infectious Enteritis Treatment Key Manufacturers in Europe
    • 12.3.3. Europe Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.3.4. Europe Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
    • 12.3.5. Europe Market Size and Forecast, By Pathogen Type, 2019 - 2032 (US$ Million)
    • 12.3.6. Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 12.3.7. Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.3.8. Europe Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.3.9. Germany
      • 12.3.9.1. Overview
      • 12.3.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.9.3. Germany Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 12.3.9.4. Germany Market Size and Forecast, By Pathogen Type, 2019 - 2032 (US$ Million)
      • 12.3.9.5. Germany Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.9.6. Germany Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 12.3.9.7. Germany Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.3.10. UK
      • 12.3.10.1. Overview
      • 12.3.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.10.3. UK Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 12.3.10.4. UK Market Size and Forecast, By Pathogen Type, 2019 - 2032 (US$ Million)
      • 12.3.10.5. UK Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.10.6. UK Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 12.3.10.7. UK Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.3.11. France
      • 12.3.11.1. Overview
      • 12.3.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.11.3. France Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 12.3.11.4. France Market Size and Forecast, By Pathogen Type, 2019 - 2032 (US$ Million)
      • 12.3.11.5. France Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.11.6. France Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 12.3.11.7. France Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.3.12. Italy
      • 12.3.12.1. Overview
      • 12.3.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.12.3. Italy Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 12.3.12.4. Italy Market Size and Forecast, By Pathogen Type, 2019 - 2032 (US$ Million)
      • 12.3.12.5. Italy Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.12.6. Italy Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 12.3.12.7. Italy Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.3.13. Spain
      • 12.3.13.1. Overview
      • 12.3.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.13.3. Spain Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 12.3.13.4. Spain Market Size and Forecast, By Pathogen Type, 2019 - 2032 (US$ Million)
      • 12.3.13.5. Spain Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.13.6. Spain Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 12.3.13.7. Spain Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.3.14. The Netherlands
      • 12.3.14.1. Overview
      • 12.3.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.14.3. The Netherlands Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 12.3.14.4. The Netherlands Market Size and Forecast, By Pathogen Type, 2019 - 2032 (US$ Million)
      • 12.3.14.5. The Netherlands Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.14.6. The Netherlands Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 12.3.14.7. The Netherlands Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.3.15. Sweden
      • 12.3.15.1. Overview
      • 12.3.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.15.3. Sweden Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 12.3.15.4. Sweden Market Size and Forecast, By Pathogen Type, 2019 - 2032 (US$ Million)
      • 12.3.15.5. Sweden Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.15.6. Sweden Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 12.3.15.7. Sweden Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.3.16. Russia
      • 12.3.16.1. Overview
      • 12.3.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.16.3. Russia Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 12.3.16.4. Russia Market Size and Forecast, By Pathogen Type, 2019 - 2032 (US$ Million)
      • 12.3.16.5. Russia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.16.6. Russia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 12.3.16.7. Russia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.3.17. Poland
      • 12.3.17.1. Overview
      • 12.3.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.17.3. Poland Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 12.3.17.4. Poland Market Size and Forecast, By Pathogen Type, 2019 - 2032 (US$ Million)
      • 12.3.17.5. Poland Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.17.6. Poland Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 12.3.17.7. Poland Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.3.18. Rest of Europe
      • 12.3.18.1. Overview
      • 12.3.18.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.3.18.3. Rest of the Europe Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 12.3.18.4. Rest of the Europe Market Size and Forecast, By Pathogen Type, 2019 - 2032 (US$ Million)
      • 12.3.18.5. Rest of the Europe Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.3.18.6. Rest of the Europe Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 12.3.18.7. Rest of the Europe Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 12.4. Asia Pacific (APAC)
    • 12.4.1. Overview
    • 12.4.2. Infectious Enteritis Treatment Key Manufacturers in Asia Pacific
    • 12.4.3. APAC Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.4.4. APAC Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
    • 12.4.5. APAC Market Size and Forecast, By Pathogen Type, 2019 - 2032 (US$ Million)
    • 12.4.6. APAC Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 12.4.7. APAC Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.4.8. APAC Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.4.9. China
      • 12.4.9.1. Overview
      • 12.4.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.9.3. China Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 12.4.9.4. China Market Size and Forecast, By Pathogen Type, 2019 - 2032 (US$ Million)
      • 12.4.9.5. China Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.9.6. China Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 12.4.9.7. China Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.4.10. India
      • 12.4.10.1. Overview
      • 12.4.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.10.3. India Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 12.4.10.4. India Market Size and Forecast, By Pathogen Type, 2019 - 2032 (US$ Million)
      • 12.4.10.5. India Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.10.6. India Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 12.4.10.7. India Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.4.11. Japan
      • 12.4.11.1. Overview
      • 12.4.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.11.3. Japan Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 12.4.11.4. Japan Market Size and Forecast, By Pathogen Type, 2019 - 2032 (US$ Million)
      • 12.4.11.5. Japan Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.11.6. Japan Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 12.4.11.7. Japan Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.4.12. South Korea
      • 12.4.12.1. Overview
      • 12.4.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.12.3. South Korea Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 12.4.12.4. South Korea Market Size and Forecast, By Pathogen Type, 2019 - 2032 (US$ Million)
      • 12.4.12.5. South Korea Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.12.6. South Korea Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 12.4.12.7. South Korea Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.4.13. Australia
      • 12.4.13.1. Overview
      • 12.4.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.13.3. Australia Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 12.4.13.4. Australia Market Size and Forecast, By Pathogen Type, 2019 - 2032 (US$ Million)
      • 12.4.13.5. Australia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.13.6. Australia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 12.4.13.7. Australia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.4.14. Indonesia
      • 12.4.14.1. Overview
      • 12.4.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.14.3. Indonesia Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 12.4.14.4. Indonesia Market Size and Forecast, By Pathogen Type, 2019 - 2032 (US$ Million)
      • 12.4.14.5. Indonesia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.14.6. Indonesia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 12.4.14.7. Indonesia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.4.15. Thailand
      • 12.4.15.1. Overview
      • 12.4.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.15.3. Thailand Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 12.4.15.4. Thailand Market Size and Forecast, By Pathogen Type, 2019 - 2032 (US$ Million)
      • 12.4.15.5. Thailand Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.15.6. Thailand Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 12.4.15.7. Thailand Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.4.16. Philippines
      • 12.4.16.1. Overview
      • 12.4.16.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.16.3. Philippines Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 12.4.16.4. Philippines Market Size and Forecast, By Pathogen Type, 2019 - 2032 (US$ Million)
      • 12.4.16.5. Philippines Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.16.6. Philippines Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 12.4.16.7. Philippines Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.4.17. Rest of APAC
      • 12.4.17.1. Overview
      • 12.4.17.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.4.17.3. Rest of APAC Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 12.4.17.4. Rest of APAC Market Size and Forecast, By Pathogen Type, 2019 - 2032 (US$ Million)
      • 12.4.17.5. Rest of APAC Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.4.17.6. Rest of APAC Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 12.4.17.7. Rest of APAC Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 12.5. Latin America (LATAM)
    • 12.5.1. Overview
    • 12.5.2. Infectious Enteritis Treatment Key Manufacturers in Latin America
    • 12.5.3. LATAM Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.5.4. LATAM Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
    • 12.5.5. LATAM Market Size and Forecast, By Pathogen Type, 2019 - 2032 (US$ Million)
    • 12.5.6. LATAM Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 12.5.7. LATAM Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.5.8. LATAM Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.5.9. Brazil
      • 12.5.9.1. Overview
      • 12.5.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.9.3. Brazil Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 12.5.9.4. Brazil Market Size and Forecast, By Pathogen Type, 2019 - 2032 (US$ Million)
      • 12.5.9.5. Brazil Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.5.9.6. Brazil Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 12.5.9.7. Brazil Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.5.10. Mexico
      • 12.5.10.1. Overview
      • 12.5.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.10.3. Mexico Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 12.5.10.4. Mexico Market Size and Forecast, By Pathogen Type, 2019 - 2032 (US$ Million)
      • 12.5.10.5. Mexico Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.5.10.6. Mexico Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 12.5.10.7. Mexico Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.5.11. Argentina
      • 12.5.11.1. Overview
      • 12.5.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.11.3. Argentina Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 12.5.11.4. Argentina Market Size and Forecast, By Pathogen Type, 2019 - 2032 (US$ Million)
      • 12.5.11.5. Argentina Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.5.11.6. Argentina Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 12.5.11.7. Argentina Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.5.12. Colombia
      • 12.5.12.1. Overview
      • 12.5.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.12.3. Colombia Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 12.5.12.4. Colombia Market Size and Forecast, By Pathogen Type, 2019 - 2032 (US$ Million)
      • 12.5.12.5. Colombia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.5.12.6. Colombia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 12.5.12.7. Colombia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.5.13. Rest of LATAM
      • 12.5.13.1. Overview
      • 12.5.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.5.13.3. Rest of LATAM Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 12.5.13.4. Rest of LATAM Market Size and Forecast, By Pathogen Type, 2019 - 2032 (US$ Million)
      • 12.5.13.5. Rest of LATAM Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.5.13.6. Rest of LATAM Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 12.5.13.7. Rest of LATAM Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
  • 12.6. Middle East and Africa
    • 12.6.1. Overview
    • 12.6.2. Infectious Enteritis Treatment Key Manufacturers in Middle East and Africa
    • 12.6.3. Middle East and Africa Market Size and Forecast, By Country, 2019 - 2032 (US$ Million)
    • 12.6.4. Middle East and Africa Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
    • 12.6.5. Middle East and Africa Market Size and Forecast, By Pathogen Type, 2019 - 2032 (US$ Million)
    • 12.6.6. Middle East and Africa Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
    • 12.6.7. Middle East and Africa Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
    • 12.6.8. Middle East and Africa Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.6.9. Saudi Arabia
      • 12.6.9.1. Overview
      • 12.6.9.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.9.3. Saudi Arabia Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 12.6.9.4. Saudi Arabia Market Size and Forecast, By Pathogen Type, 2019 - 2032 (US$ Million)
      • 12.6.9.5. Saudi Arabia Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.6.9.6. Saudi Arabia Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 12.6.9.7. Saudi Arabia Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.6.10. United Arab Emirates
      • 12.6.10.1. Overview
      • 12.6.10.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.10.3. United Arab Emirates Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 12.6.10.4. United Arab Emirates Market Size and Forecast, By Pathogen Type, 2019 - 2032 (US$ Million)
      • 12.6.10.5. United Arab Emirates Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.6.10.6. United Arab Emirates Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 12.6.10.7. United Arab Emirates Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.6.11. Israel
      • 12.6.11.1. Overview
      • 12.6.11.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.11.3. Israel Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 12.6.11.4. Israel Market Size and Forecast, By Pathogen Type, 2019 - 2032 (US$ Million)
      • 12.6.11.5. Israel Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.6.11.6. Israel Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 12.6.11.7. Israel Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.6.12. Turkey
      • 12.6.12.1. Overview
      • 12.6.12.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.12.3. Turkey Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 12.6.12.4. Turkey Market Size and Forecast, By Pathogen Type, 2019 - 2032 (US$ Million)
      • 12.6.12.5. Turkey Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.6.12.6. Turkey Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 12.6.12.7. Turkey Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.6.13. Algeria
      • 12.6.13.1. Overview
      • 12.6.13.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.13.3. Algeria Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 12.6.13.4. Algeria Market Size and Forecast, By Pathogen Type, 2019 - 2032 (US$ Million)
      • 12.6.13.5. Algeria Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.6.13.6. Algeria Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 12.6.13.7. Algeria Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.6.14. Egypt
      • 12.6.14.1. Overview
      • 12.6.14.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.14.3. Egypt Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 12.6.14.4. Egypt Market Size and Forecast, By Pathogen Type, 2019 - 2032 (US$ Million)
      • 12.6.14.5. Egypt Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.6.14.6. Egypt Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 12.6.14.7. Egypt Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)
    • 12.6.15. Rest of MEA
      • 12.6.15.1. Overview
      • 12.6.15.2. Market Analysis, Forecast, and Y-O-Y Growth Rate, 2019 - 2032, (US$ Million)
      • 12.6.15.3. Rest of MEA Market Size and Forecast, By Treatment Type, 2019 - 2032 (US$ Million)
      • 12.6.15.4. Rest of MEA Market Size and Forecast, By Pathogen Type, 2019 - 2032 (US$ Million)
      • 12.6.15.5. Rest of MEA Market Size and Forecast, By Route of Administration, 2019 - 2032 (US$ Million)
      • 12.6.15.6. Rest of MEA Market Size and Forecast, By Distribution Channel, 2019 - 2032 (US$ Million)
      • 12.6.15.7. Rest of MEA Market Size and Forecast, By End User, 2019 - 2032 (US$ Million)

13. Key Vendor Analysis- Infectious Enteritis Treatment Industry

  • 13.1. Competitive Dashboard
    • 13.1.1. Competitive Benchmarking
    • 13.1.2. Competitive Positioning
  • 13.2. Company Profiles
    • 13.2.1. GlaxoSmithKline plc
    • 13.2.2. Sanofi S.A.
    • 13.2.3. Johnson & Johnson
    • 13.2.4. Merck & Co., Inc.
    • 13.2.5. Pfizer Inc.
    • 13.2.6. Bayer AG
    • 13.2.7. Novartis AG
    • 13.2.8. AbbVie Inc.
    • 13.2.9. Eli Lilly and Company
    • 13.2.10. F. Hoffmann-La Roche Ltd
    • 13.2.11. Takeda Pharmaceutical Company Limited
    • 13.2.12. AstraZeneca plc
    • 13.2.13. Bristol-Myers Squibb Company
    • 13.2.14. Boehringer Ingelheim International GmbH
    • 13.2.15. Cipla Limited
    • 13.2.16. Gilead Sciences, Inc.
    • 13.2.17. Sun Pharmaceutical Industries Ltd

14. 360 Degree Analyst View

15. Appendix

  • 15.1. Research Methodology
  • 15.2. References
  • 15.3. Abbreviations
  • 15.4. Disclaimer
  • 15.5. Contact Us